Literature DB >> 2856856

Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). II. Relation of local breast recurrence to multicentricity.

E R Fisher, R Sass, B Fisher, R Gregorio, R Brown, L Wickerham.   

Abstract

One hundred ten local breast recurrences were observed in 1108 pathologically evaluable patients enrolled in NSABP protocol 6 who were treated by lumpectomy and followed for 5 to 95 months (average, 39 months). Eighty-six percent and 95% of all local breast recurrences were noted within 4 and 5 years, respectively, following lumpectomy. Life table analysis revealed their incidence to be 24% for those not and 6% for those receiving lumpectomy and breast irradiation. One hundred four (95%) of the breast recurrences involved the mammary parenchyma and the remaining 6 (5%) involved the skin and/or nipple only. Eleven (10%) of the former were noninvasive. The most common (86%) presentation of breast recurrence appeared to be a localized mass within or close to the quadrant of the index cancer. In 14% the recurrence not only involved the same quadrant, but was more diffuse within the breast extending to remote areas as well. This type was characterized pathologically by marked intralymphatic extension as well as involvement of the overlying skin and/or nipple after the fashion of so-called inflammatory or occult inflammatory breast cancer. The recurrences noted in the skin and/or nipple only were also pathologically characterized by intralymphatic involvement at these sites in the majority of instances. These two forms of breast recurrences appear to reflect the localized growth of highly aggressive invasive breast cancers. The concordance of histologic types and grades of the index and recurrent cancers implies that such events represent growth of overlooked tumor, a deficiency attendant with lumpectomy due to the extreme multifocal nature (not multicentricity) of some breast cancers and/or inadequacies in evaluating the lines of resection of lumpectomy specimens. Sources of error in regard to this latter are identified and guidelines for the examination of such specimens, as well as the assessment of margins, are presented. The observation that local breast recurrences noted following lumpectomy occurred within or close to the same quadrant as the index cancer, despite the presence of multicentric noninvasive cancers in 10% of the patients treated by total mastectomy, minimizes the biological and clinical significance of multicentric foci of cancer present in some breast cancers. Cancer measuring greater than or equal to 2.0 cm, having high histologic and nuclear grades, or intralymphatic extension, were found to have a statistically significant association with local breast recurrence in all patients following lumpectomy. A converse relationship was noted with tubular and scar cancers of types 1 and 4.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1986        PMID: 2856856     DOI: 10.1002/1097-0142(19860501)57:9<1717::aid-cncr2820570902>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  49 in total

1.  Pathologic Assessment of Surgical Margins on Frozen and Permanent Sections in Breast Conserving Surgery.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

2.  Analysis of fat necrosis after adjuvant high-dose-rate interstitial brachytherapy for early stage breast cancer.

Authors:  Adam A Garsa; Daniel J Ferraro; Todd Dewees; Julie A Margenthaler; Michael Naughton; Rebecca Aft; William E Gillanders; Timothy Eberlein; Melissa A Matesa; Imran Zoberi
Journal:  Brachytherapy       Date:  2012-06-20       Impact factor: 2.362

Review 3.  Laboratory handling of impalpable breast lesions: a review.

Authors:  J S Armstrong; J D Davies
Journal:  J Clin Pathol       Date:  1991-02       Impact factor: 3.411

4.  A prospective longitudinal clinical trial evaluating quality of life after breast-conserving surgery and high-dose-rate interstitial brachytherapy for early-stage breast cancer.

Authors:  Adam A Garsa; Daniel J Ferraro; Todd A DeWees; Teresa L Deshields; Julie A Margenthaler; Amy E Cyr; Michael Naughton; Rebecca Aft; William E Gillanders; Timothy Eberlein; Melissa A Matesa; Laura L Ochoa; Imran Zoberi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-22       Impact factor: 7.038

Review 5.  Partial breast irradiation: a review of techniques and indications.

Authors:  A J Stewart; A J Khan; P M Devlin
Journal:  Br J Radiol       Date:  2010-03-11       Impact factor: 3.039

6.  Oncologic and cosmetic outcome in patients with breast cancer treated with wide excision, transposition of adipose tissue with latissimus dorsi muscle, and axillary dissection followed by radiotherapy.

Authors:  M Noguchi; M Minami; M Earashi; T Taniya; I Miyazaki; H Nishijima; T Takanaka; H Kawashima; Y Saito; S Nakamura
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

Review 7.  Conservative surgery without radiotherapy in the treatment of patients with early-stage invasive breast cancer. A review.

Authors:  A Recht; M J Houlihan
Journal:  Ann Surg       Date:  1995-07       Impact factor: 12.969

8.  The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer.

Authors:  Uwe Fischer; Olivier Zachariae; Friedemann Baum; Dorit von Heyden; Matthias Funke; Torsten Liersch
Journal:  Eur Radiol       Date:  2004-07-10       Impact factor: 5.315

Review 9.  Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project.

Authors:  B Fisher; S Anderson
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

Review 10.  Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy.

Authors:  M S Anscher; P Jones; L R Prosnitz; W Blackstock; M Hebert; R Reddick; A Tucker; R Dodge; G Leight; J D Iglehart
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.